Cargando…
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535831/ https://www.ncbi.nlm.nih.gov/pubmed/28640192 http://dx.doi.org/10.3390/ijms18071338 |
_version_ | 1783253904052453376 |
---|---|
author | Adamska, Aleksandra Domenichini, Alice Falasca, Marco |
author_facet | Adamska, Aleksandra Domenichini, Alice Falasca, Marco |
author_sort | Adamska, Aleksandra |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed. |
format | Online Article Text |
id | pubmed-5535831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55358312017-08-04 Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies Adamska, Aleksandra Domenichini, Alice Falasca, Marco Int J Mol Sci Review Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed. MDPI 2017-06-22 /pmc/articles/PMC5535831/ /pubmed/28640192 http://dx.doi.org/10.3390/ijms18071338 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Adamska, Aleksandra Domenichini, Alice Falasca, Marco Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title_full | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title_fullStr | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title_full_unstemmed | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title_short | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
title_sort | pancreatic ductal adenocarcinoma: current and evolving therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535831/ https://www.ncbi.nlm.nih.gov/pubmed/28640192 http://dx.doi.org/10.3390/ijms18071338 |
work_keys_str_mv | AT adamskaaleksandra pancreaticductaladenocarcinomacurrentandevolvingtherapies AT domenichinialice pancreaticductaladenocarcinomacurrentandevolvingtherapies AT falascamarco pancreaticductaladenocarcinomacurrentandevolvingtherapies |